Femilon Tablet

Femilon (Desogestrel and Ethinyl Estradiol tablets) - Product Information

Femilon (Desogestrel and Ethinyl Estradiol tablets) is used for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives such as Femilon are highly effective with a pregnancy rate of 0.1% if used properly.

Femilon tablets are manufactured by Mylan Laboratories Ltd., India and marketed by Organon (India) Private Limited. Femilon pack has 21 hormonally active pills. Each pill contains 0.030 mg of Ethinyl Estradiol and 0.150 mg of Desogestrel. You can buy Femilon tablets online from Clear Sky pharmacy.

We also have in stock Depo Provera Contraceptive Injection which is also used for the prevention of pregnancy and the treatment of gynecological disorders.

Name of the Drug

We supply original Femilon tablets manufactured by Mylan Laboratories Ltd., India and marketed by Organon (India) Private Limited.

Manufacturer of Femilon (Desogestrel and Ethinyl Estradiol tablets)

Mylan Laboratories Ltd., India  
Marketed by Organon (India) Private Limited
Website: www.merck.co.in/en/

Active Ingredient present in Femilon Tablets

The active ingredients present in Femilon Tablets are Ethinyl Estradiol and Desogestrel. Each Femilon Tablet contains 0.030 mg of Ethinyl Estradiol and 0.150 mg of Desogestrel.

Uses of Femilon (Desogestrel and Ethinyl Estradiol tablets) - Can Femilon Prevent Pregnancy?

Oral contraceptives like Femilon tablets are highly effective method for prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. The following non-contraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral contraceptive formulations containing Ethinyl Estradiol.

Effects on menses:
increased menstrual cycle regularity
decreased blood loss and decreased incidence of iron deficiency anemia
decreased incidence of dysmenorrhea

Effects related to inhibition of ovulation:
decreased incidence of functional ovarian cysts
decreased incidence of ectopic pregnancies

Effects from long-term use:
decreased incidence of fibroadenomas and fibrocystic disease of the breast
decreased incidence of acute pelvic inflammatory disease
decreased incidence of endometrial cancer
decreased incidence of ovarian cancer

Mechanism Of This Action

Combined oral contraceptives like Femilon (Desogestrel and Ethinyl Estradiol tablets) act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus, which increase the difficulty of sperm entry into the uterus, and changes in the endometrium which reduce the likelihood of implantation.

How To Use Femilon For The First Time

In women who are using Femilon for the first time, it is recommended to start from the first day of of her menstrual period or on the first Sunday after the onset of her menstrual period (Sunday Start).

When initiating a Sunday start regimen, another method of contraception, such as condoms or spermicide, should be used for the first 7 consecutive days of taking Femilon tablets.

The recommended way is to continue taking Femilon pills for 21 days throughout and then wait for 7 days. Again, start a fresh pack from the 8th day.

Women who are shifting to Femilon from another contraceptive should be started on the same day that a new pack of the previous oral contraceptive would have been started.

The possibility of ovulation and conception before starting use of Femilon Tablets (Desogestrel and Ethinyl Estradiol tablets USP) should be considered when starting use other than the first day of of her menstrual period .

Femilon (Desogestrel and Ethinyl Estradiol tablets) - Dosage

Femilon tablet should be taken daily. One pill a day for 21 days completes the pack. Then wait for 7 days. Again, start a fresh pack from the 8th day.

From the second pack onward, you need not have to wait for the commencement of the cycle. You can start the next pack after a gap of 7 days irrespective of cycle.

Continue the pills as advised. Start the next pack after a gap of 7 days, you will have a full protection after seven days of commencement of pills.

So, for the first week, use barrier contraception like condom and later you need not take any extra precaution.

Missed Dose Instructions For Femilon Tablets

In case a patient misses 1 Femilon tablet, she should take the missed tablet as soon as she remembers. If the patient misses 2 consecutive tablets in Week 1 or Week 2, the patient should take 2 tablets the day she remembers and 2 tablets the next day. Thereafter, the patient should resume taking 1 tablet daily until she finishes the cycle pack. The patient should be instructed to use a back-up method of birth control (such as condoms or spermicide) if she has intercourse in the 7 days after she restarts her pills. If the patient misses 2 consecutive Femilon tablets in the third week or misses 3 or more white tablets in a row at any time during the cycle, the patient should throw out the rest of that cycle pack and start a new cycle pack that same day. The patient should be instructed to use a back-up method of birth control if she has intercourse in the 7 days after restarting her pills.

When Can I Expect Periods After Stopping Femilon Tablets

If You take 1 active tablet daily from Day 1 to Day 21, and your period will start 3 days to 5 days after the last tablet. Since every women is different, the period usually starts 3 to 6 days after stopping the last tablet.

Femilon Tablets Storage

Store Femilon tablets at controlled room temperature (59°F to 86°F, 15°C to 30°C). Protect from light.

Keep out of the reach and sight of children. Do not use after the expiry date stated on the package. The expiry date is the last day of the month stated.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required.

Femilon Tablets Contraindications

Femilon tablets are contraindicated in patients with a hypersensitivity to Desogestrel, Ethinyl Estradiol or any inactive ingredient present in Femilon tablets. Femilon is also contraindicated in the following cases:

• Thrombophlebitis or thromboembolic disorders
• A past history of deep vein thrombophlebitis or thromboembolic disorders
• Cerebral vascular or coronary artery disease
• Known or suspected carcinoma of the breast
• Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
• Undiagnosed abnormal genital bleeding
• Cholestatic jaundice of pregnancy or jaundice with prior pill use
• Hepatic adenomas or carcinomas
• Known or suspected pregnancy

Warnings and Precautions

Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age.

An increased risk of thromboembolic and thrombotic disease associated with the use of oral contraceptives is well established. Case control studies have found the relative risk of users compared to non-users to be 3 for the first episode of superficial venous thromboembolic disease, 4 to 11 for deep vein thrombosis or pulmonary embolism, and 1.5 to 6 for women with predisposing conditions for venous thromboembolic disease.

An increased risk of myocardial infarction has been attributed to oral contraceptive use. This risk is primarily in smokers or women with other underlying risk factors for coronary artery disease such as hypertension, hypercholesterolemia, morbid obesity, and diabetes. The relative risk of heart attack for current oral contraceptive users has been estimated to be two to six.

Oral contraceptives have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (greater than 35 years), hypertensive women who also smoke.

A positive association has been observed between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease.

The study regarding mortality from contraceptive use concluded that with the exception of oral contraceptive users 35 and older who smoke and 40 and older who do not smoke, mortality associated with all methods of birth control is low and below that associated with childbirth.

Numerous epidemiologic studies have been performed on the incidence of breast, endometrial, ovarian, and cervical cancer in women using oral contraceptives. While there are conflicting reports, most studies suggest that the use of oral contraceptives is not associated with an overall increase in the risk of developing breast cancer.

Benign hepatic adenomas are associated with oral contraceptive use, although the incidence of benign tumors is rare in the United States.

During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without Dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications such as COCs.

There have been clinical case reports of retinal thrombosis associated with the use of oral contraceptives. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately.

Extensive epidemiologic studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy

Recent studies, however, have shown that the relative risk of developing gallbladder disease among oral contraceptive users may be minimal

Oral contraceptives have been shown to cause a decrease in glucose tolerance in a significant percentage of users. Oral contraceptives containing greater than 75 micrograms of estrogens cause hyperinsulinism, while lower doses of estrogen cause less glucose intolerance

An increase in blood pressure has been reported in women taking oral contraceptives and this increase is more likely in older oral contraceptive users and with continued use.

The onset or exacerbation of migraine or development of headache with a new pattern which is recurrent, persistent, or severe requires discontinuation of oral contraceptives and evaluation of the cause.

Breakthrough bleeding and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. Non-hormonal causes should be considered and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of breakthrough bleeding, as in the case of any abnormal vaginal bleeding.

Ectopic as well as intrauterine pregnancy may occur in contraceptive failures.

Patients must be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.

Femilon (Desogestrel and Ethinyl Estradiol tablets) Side Effects

An increased risk of the following serious side effects has been associated with the use of oral contraceptives including Femilon : Thrombophlebitis and venous thrombosis with or without embolism, Arterial thromboembolism, Pulmonary embolism, Myocardial infarction, Cerebral hemorrhage, Cerebral thrombosis, Hypertension, Gallbladder disease, Hepatic adenomas or benign liver tumors.



There is evidence of an association between the following conditions and the use of oral contraceptives: Mesenteric thrombosis, Retinal thrombosis

The following side effects have been reported in patients receiving oral contraceptives like Femilon (Desogestrel and Ethinyl Estradiol tablets) and are thought to be related to the medicine: Nausea, Vomiting, Gastrointestinal symptoms (such as abdominal cramps and bloating), Breakthrough bleeding, Spotting, Change in menstrual flow, Amenorrhea, Temporary infertility after discontinuation of treatment, Edema, Melasma which may persist, Breast changes: tenderness, enlargement, secretion, Change in weight (increase or decrease), Change in cervical erosion and secretion, Diminution in lactation when given immediately postpartum, Cholestatic jaundice, Migraine, Rash (allergic), Mental depression, Reduced tolerance to carbohydrates, Vaginal candidiasis, Change in corneal curvature (steepening), Intolerance to contact lenses

Femilon (Desogestrel and Ethinyl Estradiol tablets) Overdosage

Serious adverse effects have not been reported following acute ingestion of large doses of oral contraceptives like Femilon tablets by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females.

Femilon (Desogestrel and Ethinyl Estradiol tablets) During Pregnancy

Desogestrel and Ethinyl Estradiol combined oral contraceptive tablets (Femilon) have been classified by the US FDA as Pregnancy Category X. Stop using this medication and inform your doctor immediately if you become pregnant during treatment.

Nursing Considerations

Small amounts of oral contraceptive steroids have been observed in the milk of nursing mothers and a few adverse effects on the child have been reported, including jaundice and breast enlargement. In addition, oral contraceptives given in the postpartum period could interfere with lactation by decreasing the quantity and quality of breast milk.

The nursing mother MUST be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child.
Do not use this medication without telling your doctor if you are breast-feeding a baby.

Buy Femilon Tablets Online at Only $0.56 per Pill

You can buy Femilon (Desogestrel and Ethinyl Estradiol tablets) online from Clear Sky Pharmacy at a cheap price. Femilon pills, used to prevent pregnancy are manufactured by manufactured by Mylan Laboratories Ltd., India and marketed by Organon (India) Private Limited are supplied in a blister strip of 21 tablets. The Femilon tablets cost only $0.56 per unit when you place an order for 252 tablets.

Disclaimer

The above information is provided to the best of our knowledge and in good faith, it is without a warrant of any kind, expressed or implied.

Shipping Restriction